NASDAQ · GOSS
Gossamer Bio, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GOSS: Nov 4, 2026
Gossamer Bio, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-5.55. The reported EPS for the same quarter last year was $-16.8.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-5.55 | $-3.81 | $-7.23 | 3 |
| Dec 2026 | $-4.81 | $-1.95 | $-6.40 | 3 |
| Mar 2027 | $-5.07 | $-1.82 | $-7.20 | 3 |
| Jun 2027 | $-5.15 | $-1.85 | $-7.20 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks · The Motley Fool- Fintel · Oct 28, 7:12 PM EDTGossamer Bio Stockholders Approve Share Issuance Proposal Under Securities Purchase Agreement Dated August 20, 2026Gossamer Bio, Inc. held a special meeting of stockholders on October 27, 2026. Stockholders approved, in accordance with Nasdaq Listing Rules 5635(c) and 5635(d), the potential issuance of shares of the Company's common stock, par value $0.0001 per share, pursuant to the Securiti
- Fintel · Sep 15, 12:04 PM EDTGossamer Bio Consensus Price Target Increased by 4,500% to $135.13The average one-year price target for Gossamer Bio (NASDAQGS:GOSS) has been revised to $135.13 / share. This is an increase of 4,500.00% from the prior estimate of $2.94 dated August 25, 2026. These figures represent aggregate analyst targets and do not constitute a recommendati
- RTTNews · Aug 21, 1:33 PM EDTGossamer Secures Up To $250M Financing To Advance Seralutinib Toward FDA Approval(RTTNews) – Gossamer Bio, Inc. (GOSS), announced a structured private placement of up to approximately $250 million to support seralutinib's advancement toward potential FDA approval in pulmonary arterial hypertension (PAH).
- Zacks · Aug 13, 5:15 PM EDTGossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue EstimatesGossamer Bio (GOSS) delivered earnings and revenue surprises of -100.00% and +171.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 13, 8:25 AM EDTPelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue EstimatesPelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of -119.21% and -2.88%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 12, 5:40 PM EDTKura Oncology (KURA) Reports Q2 Loss, Beats Revenue EstimatesKura Oncology (KURA) delivered earnings and revenue surprises of +13.48% and +23.61%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 30, 10:00 AM EDTPrime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleasePrime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Jul 27, 11:29 PM EDTTop Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired(RTTNews) – Today's top biotech gainers include Entera Bio, following an oversubscribed private placement financing; Gossamer, which is progressing toward a planned Seralutinib NDA submission in September; First Tracks, which has been firing on all cylinders since its Nasdaq debu
- RTTNews · Jul 27, 11:51 AM EDTGossamer Sets September NDA Filing For Seralutinib In Pulmonary Arterial Hypertension; Stock Up(RTTNews) – Gossamer Bio, Inc. (GOSS) announced that following a productive Pre-NDA Type B meeting with the U.S. FDA and receipt of the official meeting minutes, the company is moving forward with a planned NDA submission for Seralutinib in pulmonary arterial hypertension in Sept
- The Motley Fool · May 27, 4:17 PM EDTGossamer Bio (GOSS) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · May 19, 2:01 AM EDTGossamer Bio Q1 Net Loss Expands; Eyes On The Pre-NDA Meeting With FDA For Seralutinib W In Mid-June(RTTNews) – Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company, on Monday announced its financial results for the first quarter ended March 31, 2026, reflecting a wider net loss and provided a near-term milestone update for its lead investigational candidate, S
- MarketBeat · May 18, 9:05 AM EDTGossamer Bio Q1 Earnings Call HighlightsGossamer Bio (NASDAQ:GOSS) said it is moving ahead with plans to seek U.S. approval for seralutinib in pulmonary arterial hypertension, outlining a September 2026 target for a New Drug Application submission while also detailing new imaging data and steps to address its balance s
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Gossamer Bio, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.